Rebecca Teske

Statistics

Publications

Citations

521

H-Index

Active since

2014

Affiliations

Dana-Farber Cancer Institute(Current)

University of Chicago

Northwestern University

Medizinische Hochschule Hannover

Washington University in St. Louis

Rebecca Teske is an author at Dana-Farber Cancer Institute specializing in oncology, refractory acute lymphoblastic leukemia, and acute lymphoblastic leukemia treatment.

Publications per year

2014–2024

Publications

Pro-proliferative and inflammatory signaling converge on FoxO1 transcription factor in pulmonary hypertension

Rajkumar Savai, Hamza M. Al-tamari, Daniel Sedding et al. · Nature Medicine · 2014 · 279 citations

Life Sciences, Cell Biology, Molecular Biology +11

Inhibition of miR-92a improves re-endothelialization and prevents neointima formation following vascular injury

Jan‐Marcus Daniel, Daniela Penzkofer, Rebecca Teske et al. · Cardiovascular Research · 2014 · 142 citations · Full text

Life Sciences, Molecular Biology, Molecular Medicine +16

Chemotherapy-free treatment with inotuzumab ozogamicin and blinatumomab for older adults with newly diagnosed, Ph-negative, CD22-positive, B-cell acute lymphoblastic leukemia: Alliance A041703.

Matthew J. Wieduwilt, Jun Yin, Oudom Kour et al. · Journal of Clinical Oncology · 2023 · 48 citations

Medicine, Hematology, Oncology +13

Addition of Inotuzumab to a Pediatric Inspired Chemotherapy Regimen in Young Adult Patients with B-Cell Acute Lymphoblastic Leukemia: Findings from the Alliance A041501 Phase 3 Randomized Trial

Daniel J. DeAngelo, Jun Yin, Anjali S. Advani et al. · Blood · 2024 · 19 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

S117: CHEMOTHERAPY-FREE TREATMENT WITH INOTUZUMAB OZOGAMICIN AND BLINATUMOMAB FOR OLDER ADULTS WITH NEWLY-DIAGNOSED, PH-NEGATIVE, CD22-POSITIVE, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: ALLIANCE A041703

Matthew J. Wieduwilt, Jun Yin, Oudom Kour et al. · HemaSphere · 2023 · 13 citations · Full text

Medicine, Oncology, Pharmacology +14

1–5 of 7